SCHEMBL3547711

SCHEMBL3547711

COC(=O)c1cc(O)cc(OC(=S)N(C)C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.56
CA2 P00918 6/20 0.56
CA12 O43570 5/20 0.56
CA7 P43166 5/20 0.56
CA9 Q16790 5/20 0.56
CA14 Q9ULX7 5/20 0.56
LMNA P02545 4/20 0.42
KDM4E B2RXH2 3/20 0.42
POLB P06746 2/20 0.42
GAA P10253 2/20 0.42
XDH P47989 2/20 0.42
NFKB1 P19838 1/20 0.42
GFER P55789 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
FUT7 Q11130 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 5/20 0.38
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3546357 0.91 CA1 (0.44) CA1CA2CA12CA7CA9
SCHEMBL5219862 0.91 POLB (0.47) CA1CA2CA12CA7CA9
SCHEMBL3549497 0.86 CA1 (0.43) CA1CA2CA12CA7CA9
SCHEMBL26702131 0.79 ALDH1A1 (0.37) CA1CA2CA12CA7CA9
SCHEMBL9203759 0.79 PRSS1 (0.50) LMNAPOLBL3MBTL1ALDH1A1HPGD
SCHEMBL11305905 0.78 CA1 (0.56) CA1CA2CA12CA7CA9
SCHEMBL55814 0.77 CA1 (0.73) CA1CA2CA12CA7CA9
SCHEMBL3553411 0.75 HGFAC (0.53) CA1CA2CA12CA7CA9
SCHEMBL2657413 0.74 CA1 (0.63) CA1CA2CA12CA7CA9
Methyl 3,5-Dihydroxybenzoate SCHEMBL38869 0.74 CA1 (1.00) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE CA1 4363/4885CA2 4383/4885CA12 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.